屋尘螨皮下特异性免疫治疗对儿童过敏性哮喘伴鼻炎肺功能及症状的影响分析  

An analysis of the subcutaneous immunotherapy on the pulmonary function and symptoms of asthma and rhinitis in children

作　　者：吴少皎[1] 陈实[1] 陈冰[1] 王灵[1] 曾霞[1] 

机构地区：[1]海南省人民医院儿童哮喘防治中心,海口570311

出　　处：《临床耳鼻咽喉头颈外科杂志》2017年第17期1352-1355,共4页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：海南省社会发展科技专项(No:2015SF17)

摘　　要：目的:评估屋尘螨皮下注射特异性免疫治疗(SCIT)对过敏性哮喘伴鼻炎患儿肺功能及症状的影响。方法:采用前瞻性研究的方法,对144例5~17岁过敏性哮喘伴鼻炎患儿进行3年SCIT治疗,评估所有患儿治疗前及治疗1、2、3年后的肺功能(IS最大呼吸容积,FEV1)以及哮喘和鼻炎的日间、夜间症状。结果:经过3年SCIT治疗,患儿肺功能FEV1显著升高(F=243.05,P<0.01),并随着疗程的延长得到进一步的显著改善(均P<0.01);与基线相比,SCIT治疗1年时哮喘的日间、夜间症状和鼻炎的夜间症状评分显著降低(均P<0.01);与治疗1年时相比,在治疗2年时所有症状评分进一步降低(均P<0.01);治疗3年时,哮喘日间症状和鼻炎日间症状比治疗2年时进一步显著改善(P<0.05)。结论:3年标准化屋尘螨SCIT治疗能逐步改善尘螨致敏哮喘伴鼻炎患儿的肺功能及哮喘和鼻炎症状,疗效显著。Objective：To evaluate the effect of subcutaneous immunotherapy on allergic asthma and rhinitis in children. Methodz A prospective study was adopted to analysis 3 years SCIT treatment of 144 cases of children with allergic asthma and rhinitis. Before and after SCIT treatment for 1 year, 2 and 3 years, FEV1, daytime and night symptoms of asthma and rhinitis were evaluated. Rcsult; After 3 years of SCIT treatment, the FEV1 had signifi- cantly increased （F= 243.05, P〈0.01）, and with the duration of the treatment was further improvement （P〈 0.01）. Compared with the baseline, treatment 1 year in daytime, nighttime symptoms scores of asthma and night- time symptoms scores of rhinitis had significantly reduced （P〈0.01）. All symptoms were reduced further by 2 years of treatment（P〈0.01） compared with 1 year. Compared with the 2 years of treatment, daytime symptoms of asthma and rhinitis of 3 years SCIT treatment was improved significantly （P〈0.05）. Conelusion： Subcutaneous immunotherapy with 3 years in children allergic with asthma and rhinitis can play a significant effect.

关 键 词：免疫疗法 哮喘 变应性 鼻炎 变应性 儿童 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]